---
title: "Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270505565.md"
description: "The obesity drug market could shift from niche to mainstream by 2026, driven by oral GLP-1 pills from Novo Nordisk and Eli Lilly, and expanded government coverage. Novo's oral semaglutide may be approved soon, while Lilly's orforglipron targets a 2026 launch. Pills offer convenience and lower costs. A Medicare and Medicaid expansion could increase market reach. Analysts project a 30% market penetration, with potential revenue growth. Shareholders will watch approval timelines and market adoption closely."
datetime: "2025-12-22T14:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270505565.md)
  - [en](https://longbridge.com/en/news/270505565.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270505565.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/270505565.md) | [繁體中文](https://longbridge.com/zh-HK/news/270505565.md)


# Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market

Obesity drugs could shift from niche to mainstream in 2026 as oral GLP-1 pills and broader government coverage reshape demand.

Novo Nordisk and Eli Lilly lead the wave. Novo's oral semaglutide may win approval this year and reach patients early next year. Lilly's orforglipron aims for approval by the end of the first quarter of 2026 and a second-quarter launch.

Pills offer convenience and lower manufacturing costs than injectables. Trials show orforglipron trimmed body weight about 12.4% after 72 weeks while oral semaglutide showed roughly 16.6% after 64 weeks; injectables such as Zepbound often deliver larger losses.

A November deal to expand Medicare and Medicaid coverage, with copays capped near $50 a month starting in April, could widen use among older and lower-income patients. That would materially increase the addressable market.

Altogether, 2026 has a real potential to turn the tables on obesity, haddies, pills, and wider coverage: the obstructed gate can be opened. Even as the price pressure and competition set in, demand may widen rapidly should approvals remain timely.

Penetration is projected by Morgan Stanley analysts to creep to some 30% and they are projecting a higher revenue than the prevailing consensus.

Shareholders will continue to monitor timelines of approvals, practical adoption and price changes to determine whether the expectations of the market are met. It could be discontinuous instead of being linear.

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)
- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/en/news/281201382.md)
- [Novo Nordisk A/S Approves Board Changes](https://longbridge.com/en/news/280694583.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/en/news/280694679.md)
- [Novo Nordisk Updates Articles of Association and Capital Increase Mandate](https://longbridge.com/en/news/280807928.md)